Julia Binz-Lotter1, Christian Jüngst2, Markus M Rinschen1, Sybille Koehler1, Peter Zentis2, Astrid Schauss2, Bernhard Schermer1,2, Thomas Benzing1,2, Matthias J Hackl3. 1. Department II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; and. 2. Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Cologne, Germany. 3. Department II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; and matthias.hackl@uk-koeln.de.
Abstract
BACKGROUND: Inhibition of angiotensin II (AngII) signaling, a therapeutic mainstay of glomerular kidney diseases, is thought to act primarily through regulating glomerular blood flow and reducing filtration pressure. Although extravascular actions of AngII have been suggested, a direct effect of AngII on podocytes has not been demonstrated in vivo. METHODS: To study the effects of AngII on podocyte calcium levels in vivo, we used intravital microscopy of the kidney in mice expressing the calcium indicator protein GCaMP3. RESULTS: In healthy animals, podocytes displayed limited responsiveness to AngII stimulation. In contrast, in animals subjected to either adriamycin-induced acute chemical injury or genetic deletion of the podocin-encoding gene Nphs2, the consequent podocyte damage and proteinuria rendered the cells responsive to AngII and resulted in AngII-induced calcium transients in significantly more podocytes. The angiotensin type 1 receptor blocker losartan could fully inhibit this response. Also, responsiveness to AngII was at least partly mediated through the transient receptor potential channel 6, which has been implicated in podocyte calcium handling. Interestingly, loss of a single Nphs2 allele also increased podocytes' responsiveness to AngII signaling. This direct effect of AngII on injured podocytes results in increased calcium transients, which can further aggravate the underlying kidney disease. CONCLUSIONS: Our discovery that podocytes become sensitized to AngII-induced calcium signaling upon injury might explain results from large, randomized, controlled trials in which improved renal outcomes occur only in the subgroup of patients with proteinuria, indicating podocyte damage. Our findings also emphasize the need to treat every patient with a glomerular disease with either an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker.
BACKGROUND: Inhibition of angiotensin II (AngII) signaling, a therapeutic mainstay of glomerular kidney diseases, is thought to act primarily through regulating glomerular blood flow and reducing filtration pressure. Although extravascular actions of AngII have been suggested, a direct effect of AngII on podocytes has not been demonstrated in vivo. METHODS: To study the effects of AngII on podocyte calcium levels in vivo, we used intravital microscopy of the kidney in mice expressing the calcium indicator protein GCaMP3. RESULTS: In healthy animals, podocytes displayed limited responsiveness to AngII stimulation. In contrast, in animals subjected to either adriamycin-induced acute chemical injury or genetic deletion of the podocin-encoding gene Nphs2, the consequent podocyte damage and proteinuria rendered the cells responsive to AngII and resulted in AngII-induced calcium transients in significantly more podocytes. The angiotensin type 1 receptor blocker losartan could fully inhibit this response. Also, responsiveness to AngII was at least partly mediated through the transient receptor potential channel 6, which has been implicated in podocyte calcium handling. Interestingly, loss of a single Nphs2 allele also increased podocytes' responsiveness to AngII signaling. This direct effect of AngII on injured podocytes results in increased calcium transients, which can further aggravate the underlying kidney disease. CONCLUSIONS: Our discovery that podocytes become sensitized to AngII-induced calcium signaling upon injury might explain results from large, randomized, controlled trials in which improved renal outcomes occur only in the subgroup of patients with proteinuria, indicating podocyte damage. Our findings also emphasize the need to treat every patient with a glomerular disease with either an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker.
Authors: Yiming Zhou; Philip Castonguay; Eriene-Heidi Sidhom; Abbe R Clark; Moran Dvela-Levitt; Sookyung Kim; Jonas Sieber; Nicolas Wieder; Ji Yong Jung; Svetlana Andreeva; Jana Reichardt; Frank Dubois; Sigrid C Hoffmann; John M Basgen; Mónica S Montesinos; Astrid Weins; Ashley C Johnson; Eric S Lander; Michael R Garrett; Corey R Hopkins; Anna Greka Journal: Science Date: 2017-12-08 Impact factor: 47.728
Authors: Andreas D Kistler; Geetika Singh; Mehmet M Altintas; Hao Yu; Isabel C Fernandez; Changkyu Gu; Cory Wilson; Sandeep Kumar Srivastava; Alexander Dietrich; Katherina Walz; Dontscho Kerjaschki; Phillip Ruiz; Stuart Dryer; Sanja Sever; Amit K Dinda; Christian Faul; Jochen Reiser Journal: J Biol Chem Date: 2013-11-05 Impact factor: 5.157
Authors: Hatim A Zariwala; Bart G Borghuis; Tycho M Hoogland; Linda Madisen; Lin Tian; Chris I De Zeeuw; Hongkui Zeng; Loren L Looger; Karel Svoboda; Tsai-Wen Chen Journal: J Neurosci Date: 2012-02-29 Impact factor: 6.167
Authors: Daria V Ilatovskaya; Oleg Palygin; Vladislav Chubinskiy-Nadezhdin; Yuri A Negulyaev; Rong Ma; Lutz Birnbaumer; Alexander Staruschenko Journal: Kidney Int Date: 2014-03-19 Impact factor: 10.612